Mapping of matrsisome production by alveolar epithelial cells cultured in decellularized human lung scaffolds

The alveolar epithelial cells are known producers of basement membrane components of the ECM, we hypothesize that they may also contribute substantially to remodeling of interstitial ECM in the alveolar compartment in chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Primary human alveolar type II epithelial cells (AECII) were isolated from human lungs without lung disease or with end stage COPD, using the surface marker HT2-280. Isolated cells were cryopreserved without prior expansion and then directly seeded into decellularized distal lung parenchyma from healthy human lungs. Cells were cultured for 13 days with addition of a profibrotic stimuli in the form of 2 ng/ml of TGF-ß1 at day 7, to a subgroup samples with cells derived from healthy lungs. AECII cells comes from 5 healthy cell donors and 3 with COPD, decellularized scaffolds were prepared from 5 different healthy lungs. The data set contains a total of 71 samples each representing a unique cell/scaffold/treatment combination at either day7 or day 13 of culture. For each sample there exists a matched proteomics sample from mass spectrometry analysis deposited to the ProteomeXchange Consortium via the PRIDE partner repository. The data indicate a substantial potential of alveolar epithelial cells to directly contribute to matrisome turnover and ECM remodeling in the lung. Overall design: AECII cells comes from 5 healthy cell donors and 3 donors with end stage COPD. Decellularized scaffolds were prepared from 5 different healthy lungs. The data set contains a total of 71 samples each representing a unique cell/scaffold/treatment combination at either day 7 or day 13 of culture.

肺泡上皮细胞是已知可分泌细胞外基质（Extracellular Matrix, ECM）基底膜组分的细胞，我们假设在慢性阻塞性肺疾病（Chronic Obstructive Pulmonary Disease, COPD）、特发性肺纤维化（Idiopathic Pulmonary Fibrosis, IPF）等慢性肺部疾病中，它们也可对肺泡腔室的间质ECM重塑做出显著贡献。本研究使用表面标志物HT2-280，从无肺部疾病或终末期COPD的人肺组织中分离原代人肺泡II型上皮细胞（Alveolar Type II Epithelial Cells, AECII）。分离得到的细胞未经体外扩增即被冻存，随后直接接种于健康人肺的脱细胞远端肺实质支架中。对于来自健康肺的细胞亚组样本，我们在培养第7天时加入2 ng/ml的转化生长因子-β1（Transforming Growth Factor-β1, TGF-β1）作为促纤维化刺激因子，持续培养至第13天。本次实验的AECII细胞来自5名健康供体与3名终末期COPD供体，脱细胞支架则取自5个不同的健康肺组织。本数据集共包含71份样本，每份样本对应培养第7天或第13天时的一组独特的细胞/支架/处理组合。针对每份样本，均存在通过PRIDE合作库提交至ProteomeXchange联盟的质谱分析匹配蛋白质组学样本。实验数据表明，肺泡上皮细胞具备直接参与肺基质组更新与ECM重塑的巨大潜力。总体实验设计：AECII细胞来自5名健康供体与3名终末期COPD供体，脱细胞支架取自5个不同的健康肺组织，数据集共包含71份样本，每份样本对应培养第7天或第13天时的一组独特的细胞/支架/处理组合。